Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.66 |
| ▸ | BTK | Q06187 | 9/20 | 0.66 |
| ▸ | LCK | P06239 | 8/20 | 0.61 |
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22347041 | 1.00 | JAK3 (0.66) | JAK3BTKLCKEGFRMAP4K4 | |
| SCHEMBL22347040 | 1.00 | JAK3 (0.66) | JAK3BTKLCKEGFRMAP4K4 | |
| SCHEMBL22346055 | 0.89 | JAK3 (0.62) | JAK3BTKLCKEGFR | |
| SCHEMBL22346054 | 0.89 | JAK3 (0.62) | JAK3BTKLCKEGFR | |
| SCHEMBL29556943 | 0.87 | JAK3 (0.76) | JAK3BTKLCKEGFR | |
| SCHEMBL22347032 | 0.87 | JAK3 (0.76) | JAK3BTKLCKEGFR | |
| SCHEMBL22347034 | 0.87 | JAK3 (0.76) | JAK3BTKLCKEGFR | |
| SCHEMBL16764202 | 0.86 | JAK3 (0.77) | JAK3BTKLCKEGFR | |
| SCHEMBL16764203 | 0.86 | JAK3 (0.77) | JAK3BTKLCKEGFR | |
| SCHEMBL16786059 | 0.86 | JAK3 (0.76) | JAK3BTKLCKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4570320-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4069237-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| EP-4069237-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220143195-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | PSMB2, PSME3, PSMB3 | JAK3 508/4885BTK 5/4885LCK 240/4885 |
| US-20220143195-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | JAK3 623/4885BTK 3/4885LCK 125/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | JAK3 553/4885BTK 1/4885LCK 80/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | JAK3 553/4885BTK 1/4885LCK 80/4885 |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, BCL9, BCL9L | JAK3 161/4885BTK 1/4885LCK 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.